Should I buy or sell BrainsWay stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BWAY shares. View BWAY analyst ratings or view top-rated stocks .

What is BrainsWay's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price objectives for BrainsWay's shares. Their BWAY share price targets range from $3.00 to $12.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts .

How have BWAY shares performed in 2024?

BrainsWay's stock was trading at $6.48 at the start of the year. Since then, BWAY shares have decreased by 26.1% and is now trading at $4.79. View the best growth stocks for 2024 here .

Are investors shorting BrainsWay?

BrainsWay saw a decrease in short interest in March. As of March 31st, there was short interest totaling 74,800 shares, a decrease of 33.0% from the March 15th total of 111,600 shares. Based on an average trading volume of 125,000 shares, the days-to-cover ratio is presently 0.6 days. View BrainsWay's Short Interest .

When is BrainsWay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our BWAY earnings forecast .

How were BrainsWay's earnings last quarter?

BrainsWay Ltd. (NASDAQ:BWAY) announced its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $9.03 million for the quarter, compared to analysts' expectations of $8.40 million. BrainsWay had a negative trailing twelve-month return on equity of 10.05% and a negative net margin of 13.20%. During the same quarter in the prior year, the company earned ($0.12) earnings per share.

What guidance has BrainsWay issued on next quarter's earnings?

BrainsWay issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $37.0 million-$40.0 million, compared to the consensus revenue estimate of $35.7 million.

What other stocks do shareholders of BrainsWay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV) , Advanced Micro Devices (AMD) , Enterprise Products Partners (EPD) , Pfizer (PFE) , Neuronetics (STIM) , Boingo Wireless (WIFI) , Eastman Chemical (EMN) , Enbridge (ENB) and Energy Transfer (ET) .

When did BrainsWay IPO?

BrainsWay (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.

How do I buy shares of BrainsWay?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:BWAY

BrainsWay (BWAY) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free BWAY Stock Alerts

$4.79

-0.26 (-5.15%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.61
▼
$5.18
50-Day Range: $4.79
▼
$7.14
52-Week Range: $1.38
▼
$7.61

Volume: 79,897 shs
Average Volume: 124,264 shs
Market Capitalization: $79.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get BrainsWay alerts:

BrainsWay MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 46.1% Upside
$7.00 Price Target
Short Interest: Healthy
0.45% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.02) to $0.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

437th out of 918 stocks

Surgical & Medical Instruments Industry

43rd out of 91 stocks

3.3

Analyst's Opinion

Consensus Rating
BrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
BrainsWay has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the outstanding shares of BrainsWay have been sold short.
Short Interest Ratio / Days to Cover
BrainsWay has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BrainsWay has recently decreased by 32.97%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BrainsWay does not currently pay a dividend.
Dividend Growth
BrainsWay does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BWAY.

2.7

News and Social Media Coverage

News Sentiment
BrainsWay has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BrainsWay this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for BWAY on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BrainsWay insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.11% of the stock of BrainsWay is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BrainsWay are expected to grow in the coming year, from ($0.02) to $0.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BrainsWay is -36.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BrainsWay is -36.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BrainsWay has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About BrainsWay Stock (NASDAQ:BWAY)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BWAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BWAY Stock News Headlines

April 8, 2024 | msn.com

Outset Medical stock rallies 22% as BTIG starts coverage at buy

April 6, 2024 | stockhouse.com

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS(TM) to Treat Parkinson's Disease

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 5, 2024 | uk.investing.com

BrainsWay Announces Published Review Results Highlighting Potential of Deep ™S™ to Treat Parkinson's Disease

April 4, 2024 | finanznachrichten.de

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS to Treat Parkinson's Disease

April 4, 2024 | globenewswire.com

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

March 31, 2024 | msn.com

Compare with Sofwave Medical Ltd (SOFW)

March 28, 2024 | finance.yahoo.com

BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 18, 2024 | finance.yahoo.com

BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems

March 18, 2024 | globenewswire.com

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

March 17, 2024 | investorplace.com

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

March 11, 2024 | markets.businessinsider.com

Buy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion Potential

March 8, 2024 | seekingalpha.com

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

March 6, 2024 | msn.com

Brainsway beats top-line and bottom-line estimates; initiates FY24 outlook

March 6, 2024 | benzinga.com

2BWAY : BrainsWay Earnings Preview

March 6, 2024 | investorplace.com

BWAY Stock Earnings: BrainsWay Beats Revenue for Q4 2023

March 6, 2024 | globenewswire.com

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

February 27, 2024 | seekingalpha.com

BrainsWay Q4 Earnings Preview

February 21, 2024 | finance.yahoo.com

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 21, 2024 | globenewswire.com

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

January 16, 2024 | finance.yahoo.com

Zacks.com featured highlights VirTra, Universal Stainless & Alloy, Carrols Restaurant, BrainsWay and Virco

January 11, 2024 | benzinga.com

BrainsWay Stock (NASDAQ:BWAY) Dividends: History, Yield and Dates

January 10, 2024 | finance.yahoo.com

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

January 3, 2024 | finance.yahoo.com

Recent Price Trend in Brainsway Ltd. Sponsored ADR (BWAY) is Your Friend, Here's Why

January 2, 2024 | finance.yahoo.com

Best Momentum Stocks to Buy for January 2nd

January 1, 2024 | msn.com

Analysts Think This Small-Cap Stock Could Soar in 2024

See More Headlines

Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:BWAY
CUSIP: N/A
CIK: 1505065
Web: www.brainsway.com
Phone: (722) 582-4030
Fax: N/A
Employees: 134
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $12.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +38.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,200,000.00
Net Margins: -13.20%
Pretax Margin: -12.41%
Return on Equity: -10.05%
Return on Assets: -6.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.68
Quick Ratio: 5.30

Sales & Book Value

Annual Sales: $31.78 million
Price / Sales: 2.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.50 per share
Price / Book: 2.02

Miscellaneous

Outstanding Shares: 16,640,000
Free Float: 13,476,000
Market Cap: $84.03 million
Optionable: Not Optionable
Beta: 1.20

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Hadar Levy (Age 50)
Chief Executive Officer
Comp: $470.16k
Mr. Avner Hagai (Age 68)
Founder & Director
Comp: $47.37k
Prof. Abraham Zangen (Age 54)
Co-Founder, Member of Scientific Advisory Board & Director
Comp: $77.2k
Mr. Christopher J. Boyer Ph.D. (Age 46)
Vice President of Global Marketing
Comp: $337.95k
Dr. Yiftach Roth Ph.D. (Age 53)
Founder & Chief Scientific Officer
Comp: $108k
Mr. Ido Marom
Chief Financial Officer
Mr. Menachem C. Klein Esq.
VP, General Counsel & Corporate Secretary
Dr. Aron Tendler
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BWAY Stock Analysis - Frequently Asked Questions

Should I buy or sell BrainsWay stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BWAY shares.
View BWAY analyst ratings or view top-rated stocks.
What is BrainsWay's stock price target for 2024?: 3 Wall Street research analysts have issued twelve-month price objectives for BrainsWay's shares. Their BWAY share price targets range from $3.00 to $12.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 46.1% from the stock's current price.
View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts.
How have BWAY shares performed in 2024?: BrainsWay's stock was trading at $6.48 at the start of the year. Since then, BWAY shares have decreased by 26.1% and is now trading at $4.79.
View the best growth stocks for 2024 here.
Are investors shorting BrainsWay?: BrainsWay saw a decrease in short interest in March. As of March 31st, there was short interest totaling 74,800 shares, a decrease of 33.0% from the March 15th total of 111,600 shares. Based on an average trading volume of 125,000 shares, the days-to-cover ratio is presently 0.6 days.
View BrainsWay's Short Interest.
When is BrainsWay's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our BWAY earnings forecast.
How were BrainsWay's earnings last quarter?: BrainsWay Ltd. (NASDAQ:BWAY) announced its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $9.03 million for the quarter, compared to analysts' expectations of $8.40 million. BrainsWay had a negative trailing twelve-month return on equity of 10.05% and a negative net margin of 13.20%. During the same quarter in the prior year, the company earned ($0.12) earnings per share.

What guidance has BrainsWay issued on next quarter's earnings?: BrainsWay issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $37.0 million-$40.0 million, compared to the consensus revenue estimate of $35.7 million.
What other stocks do shareholders of BrainsWay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).
When did BrainsWay IPO?: BrainsWay (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.
How do I buy shares of BrainsWay?: Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BWAY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial